Mankind Pharma has executed a Business Transfer Agreement to acquire the Branded Generic Business relating to Women Health Rx Portfolio from Bharat Serums & Vaccines Limited, a wholly-owned subsidiary. The acquisition consideration is ₹797 Crores, subject to closing adjustments. This strategic move expands Mankind Pharma’s product offerings in the women’s health segment. The acquisition is expected to close pending fulfillment of pre-conditions.
Portfolio Acquisition
Mankind Pharma has entered into an agreement to acquire a significant portfolio in the women’s health sector. The acquisition was formalized on October 10, 2025, through a Business Transfer Agreement (BTA) with Bharat Serums & Vaccines Limited (“BSV”). This acquisition strengthens Mankind Pharma’s position in the branded generic business.
Financial Details
The agreed-upon consideration for the acquisition of the Women Health Rx Portfolio is ₹797 Crores. This figure is subject to standard closing adjustments as outlined in the BTA. The consideration will be paid in two installments.
Payment Structure
The payment structure will be as follows:
- 50% of the sale consideration will be paid on the Closing Date.
- The balance of the sale consideration will be payable within 150 days from the Closing Date.
Closing Conditions
The completion of the acquisition is subject to standard pre-conditions. Closing actions and other terms and conditions are described in the BTA.
Source: BSE